title: FK506 may reduce early liver injury following living related liver transplantation.
abstract: OBJECTIVE
  We investigated the influence of FK506 which has been used frequently after transplant surgery as an immunosuppressant, on liver injury after partial hepatectomy by comparing laboratory data from donors and recipients after liver transplantation.
  
  
  METHODS
  Seventeen donors and respective recipients who underwent living related donor liver transplantation were included in the present study. Serum levels of transaminases and cytokines were measured and compared preoperatively and in the early period after the operation.
  
  
  RESULTS
  Serum level of asparaginic acid aminotransferase in the postoperative day 1 was significantly higher in the donor group. Serum levels of alanine aminotransferase in the early period after the operation were significantly higher in the donor group. Serum levels of interferon y and soluble Fas ligand in the early period after the operation were significantly higher in the donor group. Steroid doses administered were significantly higher in the recipient group.
  
  
  CONCLUSIONS
  FK506 administration and steroid administration in larger doses were thought to reduce serum transaminase levels of the recipient group. These findings might suggest that cell-mediated immunity weigh heavier than the operation time of ischemia-reperfusion injury as a cause of liver injury after partial hepatectomy.
authors.affiliation: Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Science Niigata, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kato
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Sato
authors.forename: Isao
authors.initials: I
authors.lastname: Kurosaki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Hirano
authors.forename: Hideki
authors.initials: H
authors.lastname: Nakatsuka
authors.forename: Takashi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kameyama
authors.forename: Takaoki
authors.initials: T
authors.lastname: Watanabe
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Shirai
authors.forename: Katsuyoshi
authors.initials: K
authors.lastname: Hatakeyama
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D016207:Cytokines / Q000097:blood; D053222:Fas Ligand Protein / Q000097:blood; D005260:Female; D049670:History, 17th Century; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007371:Interferon-gamma / Q000097:blood; D008099:Liver / Q000293:injuries*; D016031:Liver Transplantation / Q000009:adverse effects*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000008:administration & dosage*; D000637:Transaminases / Q000097:blood*; D016896:Treatment Outcome
chemical_list: D016207:Cytokines; D053222:Fas Ligand Protein; D007166:Immunosuppressive Agents; D007371:Interferon-gamma; D000637:Transaminases; D000410:Alanine Transaminase; D016559:Tacrolimus